Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Bellen
company
About
A Chinese medical contract research organization.
- 501 - 1000
Highlights
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $30M
- Industries
- Biotechnology,Chemical,Medical,Pharmaceutical,Product Research
- Founded date
- Jan 1, 2007
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
Bellen Chemistry is a premier provider of a variety of heterocycles. Our activity is focused on the design and development of novel molecules,6361413375267061158256368.jpgintermediates for the Chemical and Pharmaceutical industries. Bellen Chemistryhas a strong R&D team with a talent pool of 200+ trained scientists. We have excellent track records, as we deliver unrivalled chemical innovation to our customers worldwide.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$30M
Bellen has raised a total of
$30M
in funding over 2 rounds. Their latest funding was raised on
Sep 27, 2018 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 27, 2018 | Series C | $30M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Bellen is funded by 2 investors.
Junlian Yikang
and QianHai Equity Investment
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series C |
|
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
